Search Results - "Drilon, A."

TRK inhibitors in TRK fusion-positive cancers by Drilon, A

“…TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were granted…”
Get full text

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry by Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.

“…Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of…”
Get full text

Selective RET kinase inhibition for patients with RET-altered cancers by Subbiah, V., Velcheti, V., Tuch, B.B., Ebata, K., Busaidy, N.L., Cabanillas, M.E., Wirth, L.J., Stock, S., Smith, S., Lauriault, V., Corsi-Travali, S., Henry, D., Burkard, M., Hamor, R., Bouhana, K., Winski, S., Wallace, R.D., Hartley, D., Rhodes, S., Reddy, M., Brandhuber, B.J., Andrews, S., Rothenberg, S.M., Drilon, A.

“…Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers. However, the clinical activity of multikinase…”
Get full text

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents by Laskin, J., Liu, S.V., Tolba, K., Heining, C., Schlenk, R.F., Cheema, P., Cadranel, J., Jones, M.R., Drilon, A., Cseh, A., Gyorffy, S., Solca, F., Duruisseaux, M.

“…Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to deregulated activity. Fusions involving the neuregulin-1…”
Get full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

COVID-19 in patients with lung cancer by Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

“…Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and…”
Get full text

Characterization of on-target adverse events caused by TRK inhibitor therapy by Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C.J., Murciano-Goroff, Y.R., Rosen, E., Guo, R., Basu, E., Li, B.T., Harding, J.J., Iyer, G., Jhaveri, K., Gounder, M.M., Shukla, N.N., Roberts, S.S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D.M., Drilon, A.

“…The tropomyosin receptor kinase (TRK) pathway controls appetite, balance, and pain sensitivity. While these functions are reflected in the on-target adverse…”
Get full text

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research by Belli, C., Penault-Llorca, F., Ladanyi, M., Normanno, N., Scoazec, J.-Y., Lacroix, L., Reis-Filho, J.S., Subbiah, V., Gainor, J.F., Endris, V., Repetto, M., Drilon, A., Scarpa, A., André, F., Douillard, J.-Y., Curigliano, G.

“…Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities…”
Get full text

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) by Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D.M., Hechtman, J., Wei, G., Cam, N.R., Christiansen, J., Luo, D., Maneval, E.C., Bauer, T., Patel, M., Liu, S.V., Ou, S.H.I., Farago, A., Shaw, A., Shoemaker, R.F., Lim, J., Hornby, Z., Multani, P., Ladanyi, M., Berger, M., Katabi, N., Ghossein, R., Ho, A.L.

“…Mammary analogue secretory carcinoma (MASC) is a recently described pathologic entity. We report the case of a patient with an initial diagnosis of salivary…”
Get full text

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022 by Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., Stathis, A., Steeghs, N., Yap, C., Yap, T.A., Ratain, M., Seymour, L.

“…In 2021, the Food and Drug Administration Oncology Center of Excellence announced Project Optimus focusing on dose optimization for oncology drugs. The…”
Get full text

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers by Drilon, A., Bergagnini, I., Delasos, L., Sabari, J., Woo, K.M., Plodkowski, A., Wang, L., Hellmann, M.D., Joubert, P., Sima, C.S., Smith, R., Somwar, R., Rekhtman, N., Ladanyi, M., Riely, G.J., Kris, M.G.

“…RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in…”
Get full text

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected by Pietrantonio, F., Di Nicolantonio, F., Schrock, A.B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P., Drilon, A., Hechtman, J.F., Christiansen, J., Gowen, K., Frampton, G.M., Gasparini, P., Rossini, D., Gigliotti, C., Kim, S.T., Prisciandaro, M., Hodgson, J., Zaniboni, A., Chiu, V.K., Milione, M., Patel, R., Miller, V., Bardelli, A., Novara, L., Wang, L., Pupa, S.M., Sozzi, G., Ross, J., Di Bartolomeo, M., Bertotti, A., Ali, S., Trusolino, L., Falcone, A., de Braud, F., Cremolini, C.

“…Recognition of rare molecular subgroups is a challenge for precision oncology and may lead to tissue-agnostic approval of targeted agents. Here we aimed to…”
Get full text

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies by Barrios, D.M., Phillips, G.S., Geisler, A.N., Trelles, S.R., Markova, A., Noor, S.J., Quigley, E.A., Haliasos, H.C., Moy, A.P., Schram, A.M., Bromberg, J., Funt, S.A., Voss, M.H., Drilon, A., Hellmann, M.D., Comen, E.A., Narala, S., Patel, A.B., Wetzel, M., Jung, J.Y., Leung, D.Y.M., Lacouture, M.E.

“…Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous…”
Get full text

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers by Li, B.T., Drilon, A., Johnson, M.L., Hsu, M., Sima, C.S., McGinn, C., Sugita, H., Kris, M.G., Azzoli, C.G.

“…While previous studies have reported on the prognostic value of total plasma cell-free deoxyribonucleic acid (cfDNA) in lung cancers, few have prospectively…”
Get full text

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients by Ross, D.S., Liu, B., Schram, A.M., Razavi, P., Lagana, S.M., Zhang, Y., Scaltriti, M., Bromberg, J.F., Ladanyi, M., Hyman, D.M., Drilon, A., Zehir, A., Benayed, R., Chandarlapaty, S., Hechtman, J.F.

“…Kinase fusions are rare and poorly characterized in breast cancer (BC). We aimed to characterize kinase fusions within a large cohort of advanced BC. A total…”
Get full text

The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants by Drilon, A, Hofmann, N, Flynn, D, Smith, B, Davare, M

“…Background: Oncoproteins resulting from NTRK family gene rearrangements function as dominant drivers in multiple malignancies. Ongoing clinical trials…”
Get full text

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers by Wu, J., Liu, D., Offin, M., Lezcano, C., Torrisi, J. M., Brownstein, S., Hyman, D. M., Gounder, M. M., Abida, W., Drilon, A., Harding, J. J., Sullivan, R. J., Janku, F., Welsch, D., Varterasian, M., Groover, A., Li, B. T., Lacouture, M. E.

“…Summary Background Ulixertinib is the first-in-class ERK1/2 kinase inhibitor with encouraging clinical activity in BRAF- and NRAS- mutant cancers. Dermatologic…”
Get full text

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach by Tan, D.S.W., Lassen, U.N., Albert, C.M., Kummar, S., van Tilburg, C., Dubois, S.G., Geoerger, B., Mascarenhas, L., Federman, N., Basu-Mallick, A., Doz, F., Berlin, J.D., Oh, D.-Y., Bielack, S., McDermott, R., Cruickshank, S., Ku, N.C., Cox, M.C., Drilon, A., Hong, D.S.

Get full text

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach by Lassen, U N, Albert, C M, Kummar, S, van Tilburg, C M, Dubois, S G, Geoerger, B, Mascarenhas, L, Federman, N, Schilder, R J, Doz, F, Berlin, J D, Oh, D-Y, Bielack, S S, McDermott, R, Tan, D S, Cruickshank, S, Ku, N C, Cox, M C, Drilon, A, Hong, D S

Get full text

Activity of larotrectinib in TRK fusion lung cancer by Drilon, A., Kummar, S., Moreno, V., Patel, J., Lassen, U., Rosen, L., Childs, B.H., Nanda, S., Cox, M.C., Ku, N.C., Farago, A.F.

Get full text